Neurobo Pharmaceuticals Inc (NRBO) |
|
3.93 -0.04 (-1.01%)
|
03-07 04:41 |
|
Open: |
3.98 |
Pre. Close: |
3.97 |
|
High:
|
4.1 |
Low:
|
3.63 |
|
Volume:
|
159,405 |
Market Cap:
|
87M |
|
|
|
|
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.109 - 4.133 |
4.133 - 4.152 |
|
Low:
|
3.577 - 3.606 |
3.606 - 3.628 |
|
Close:
|
3.888 - 3.935 |
3.935 - 3.97 |
|
Technical analysis |
as of: 2021-03-05 5:11:18 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.07  One year: 7.21 |
| Support: |
Support1: 3.63 Support2: 3.02 |
| Resistance: |
Resistance1: 5.20 Resistance2: 6.17 |
| Pivot: |
4.82 |
| Moving Average: |
MA(5): 4.26 MA(20): 4.99
MA(100): 5.52 MA(250): 8.23 |
| MACD: |
MACD(12,26): -0.38 Signal(9): -0.26 |
| Stochastic oscillator: |
%K(14,3): 11.27 %D(3): 15.20 |
| RSI: |
RSI(14): 31.94 |
| 52-week: |
High: 29.71 Low: 3.63 Change(%): -74.0 |
| Average Vol(K): |
3-Month: 41244 10-Days: 27306 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.NRBO has closed above bottom band by 10.9%. Bollinger Bands are 74.9% wider than normal. The large width of the bands suggest high volatility as compared to NRBO's normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 05 Mar 2021
NeuroBo Pharmaceuticals to Participate in HC Wainwright Global Life Sciences Conference - PRNewswire
Fri, 05 Mar 2021
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study - Yahoo Finance
Thu, 04 Mar 2021
Neurobo Pharmaceuticals Inc (NRBO) Stock Falls -10.34% This Week; Should You Buy? - InvestorsObserver
Wed, 03 Mar 2021
Is Neurobo Pharmaceuticals Inc (NRBO) Stock a Bad Value Wednesday? - InvestorsObserver
Tue, 02 Mar 2021
Do Analysts Agree Tuesday on Neurobo Pharmaceuticals Inc (NRBO) Stock's Target Price? - InvestorsObserver
Tue, 23 Feb 2021
Is Neurobo Pharmaceuticals Inc (NRBO) Stock a Bad Value Tuesday? - InvestorsObserver
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
22 |
| Shares Float (M) |
5 |
|
% Held by Insiders
|
1.99 |
|
% Held by Institutions
|
6.45 |
|
Shares Short (K)
|
140 |
|
Shares Short P. Month (K)
|
122 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-36.9 |
|
Return on Equity (ttm)
|
-160.2 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.460 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-10 |
|
Levered Free Cash Flow (M)
|
-4 |
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
-8.99 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
